KZR vs AVDL โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AVDL Captures Institutional Edge (3โ1 Pillars ยท 8โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Avadel Pharmaceuticals plc Ordinary Share (AVDL) driven by superior Valuation, Growth & Margin, Momentum & Technical while KZR counters with relative strength in Options & Structure. Fundamentally, KZR trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus AVDL at 28.8x Forward P/E and 2.5% operating margin (+54.9% YoY). In options structure, KZR sits in UNCLASSIFIED (9th %ile IV; Dealer Gamma Walls on Pro) against AVDL sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | KZR | AVDL | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $54.4M | $2.1B | Larger Scale | AVDL |
| Trailing P/E Ratio Valuation | N/M | 16.8x | Lower Multiple | AVDL |
| Forward P/E Ratio Valuation | N/M | 28.8x | Lower Multiple | AVDL |
| Revenue Growth (YoY) Growth | +0.0% | +54.9% | Higher Growth | AVDL |
| Operating Margin (TTM) Profitability | 0.0% | 2.5% | Higher Margin | AVDL |
| Net Profit Margin Profitability | 0.0% | -0.1% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -59.9% | -0.3% | Higher ROE | AVDL |
| 52-Week Range Position Momentum | 94% ($4โ$8) | 89% ($6โ$24) | Stronger Trend | KZR |
| Beta / 30D Volatility Risk Regime | 0.60ฮฒ ยท 8% Vol | 0.14ฮฒ ยท 2% Vol | Lower Realized Risk | AVDL |
| Unified Institutional Score Composite Signal | 60.1 / 100 (BUY) | 62.9 / 100 (BUY) | Higher Composite | AVDL |